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1 |  INTRODUCTION
Tendinopathy is a highly prevalent musculoskeletal pathol-
ogy associated with overuse injury. Tendinopathies account 
for 30%-50% of sporting injuries and a large portion of 
orthopedic referrals from primary care.1,2 Dysregulated ma-
trix repair elicited by persistent pathological inflammation is 
the main causative factor in the development of established 
tendinopathy.3 Injured tendons display irregular tissue archi-
tecture and weakened biomechanical properties, primarily 
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Tendinopathy is a highly prevalent musculoskeletal pathology associated with in-
cremental injury as result of repetitive microtrauma. We sought to explore the 
physiological significance of stromal “activation” signatures in a human model of 
tendinopathy. Torn supraspinatus tendon and matched intact subscapularis tendon 
biopsies were collected from patients undergoing shoulder surgery while healthy 
tendon was collected from patients undergoing anterior cruciate ligament (ACL) re-
construction. Expression of stromal activation markers was analyzed at transcript/
protein level using qRT-PCR and immunohistochemistry. Gene expression of stro-
mal activation markers was silenced by siRNA-mediated knockdown or induced by 
IL-1β stimulation. Expression of “activation” markers podoplanin, VCAM-1 and 
CD248 was identified in human tendon tissue. Podoplanin and VCAM-1 expression 
were significantly increased in tendinopathic tissue. Knockdown of podoplanin and 
VCAM-1 in normal and tendinopathic tenocytes did not have any significant ef-
fect on expression of matrix genes COL1A1, COL3A1, TNC, or DCN. Similarly, no 
changes in release of inflammatory mediators IL-6, IL-8, and CCL2 were observed 
in podoplanin/VCAM-1 knockdown cultures. Our data suggest that silencing ex-
pression of stromal “activation” markers does not affect the intrinsic inflammatory 
profile or matrix regulatory behavior of tenocytes. We propose that the term “activa-
tion” is more appropriately reflected by alterations in tenocyte behavior that induce 
changes in the stromal microenvironment and overall tissue architecture rather than 
identification through potentially arbitrary phenotypic traits.
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attributed to altered collagen synthesis and matrix deposi-
tion.4 Furthermore, an incomplete healing response is com-
mon and consequent propensity for re-injury presents many 
challenges in a clinical setting.5
Historically, the stroma was considered to be immuno-
logically inert and exist purely as a tissue-specific scaffold 
that participates in wound healing responses.6 Excessive 
loading of tendons was considered the main pathological 
stimulus for degeneration, conferred by the mechanosens-
ing properties of tenocytes.7 Tenocytes are fibroblast-like 
cells that comprise the main cellular component of the ten-
don stroma. Tenocytes regulate the structure and function 
of healthy tendons and participate in tissue repair follow-
ing periods of acute inflammation.5 It has been postulated 
that recruitment, influx, and retention of immune cells are 
controlled by cytokine and chemokine gradients created by 
resident stromal cells.8
It is thought stromal cell properties are defined ac-
cording to tissue structure at an individual site and the 
external stimuli they receive.9 For example, tenocytes are 
interspersed uniformly throughout the tendon matrix and 
are adapted to respond to mechanical force and damage-as-
sociated molecular patterns (DAMPs) through pattern rec-
ognition receptors.10 Recent studies have suggested that 
repeated exposure to pathological stimuli induce epigen-
etic changes that drive a persistent state of activation.11,12 
Under certain conditions, such as chronic inflammation, 
it has been postulated that these genetic changes are ac-
companied by phenotypic alterations including constitutive 
expression of cell surface receptors termed stromal “activa-
tion” markers.13 Traditionally, fibroblasts were perceived 
as a homogenous population with a relatively limited func-
tional capacity. However, emerging evidence suggests that 
fibroblasts display a degree of plasticity and can exist as 
functionally distinct populations analogous to subsets of 
leukocytes.14
Studies have highlighted the presence of “activation” 
markers in several inflammatory pathologies including 
rheumatoid arthritis (RA) and cancer where surface marker 
expression has been associated with “aggressive” and “in-
vasive” stromal cell phenotypes.15-17 More recently, their 
presence has been documented in soft tissue diseases 
including adhesive capsulitis and tendinopathy; how-
ever, evidence pertaining to their functional significance 
in the context of inflammation and matrix regulation is 
limited.18,19
A recent study reported sustained expression of stromal 
fibroblast activation markers podoplanin, vascular cell ad-
hesion molecule 1 (VCAM-1/CD106), and CD248 (endo-
sialin/ tumor endothelial marker-1) in tendinopathic biopsy 
samples that persisted up to 4 years post-treatment. It was 
also reported this sustained stromal activation marker ex-
pression was induced in cultured cells in response to an 
inflammatory stimulus.19 Podoplanin is a small cell surface 
mucin-like glycoprotein expressed on a number of cells 
including fibroblasts and macrophages. Its expression is 
upregulated under high levels of inflammation associated 
with chronic conditions such as RA, psoriasis, and mul-
tiple sclerosis (MS).20:Little is known about the physio-
logical properties of podoplanin; however, recent studies 
have highlighted its role in regulating the inflammatory 
reaction and immune cell infiltration during sepsis.21 
VCAM-1 (vascular cell adhesion molecule-1) expression is 
associated with the progression of several immunological 
disorders including RA, asthma, and cancer.22 It is primar-
ily expressed on the surface of endothelial cells; however, 
its expression is upregulated in other cell types including 
fibroblasts and macrophages under inflammatory condi-
tions.23 CD248 is a transmembrane glycoprotein highly ex-
pressed in most cancers, RA, and diseases associated with 
excessive fibrosis.24 In addition, CD248 acts as a receptor 
for extracellular matrix proteins including collagen I and 
fibronectin.25
The immune landscape in tendinopathy is diverse and 
host to several functionally and phenotypically distinct pop-
ulations of cells.3 “Activation” proteins are generally absent 
from the stroma of normal tissue which suggests they play a 
role in disease pathology.26 This study sought to identify rela-
tionships between expression of surface “activation” proteins 
and regulation of inflammation and matrix turnover by teno-
cytes using a loss-of-function approach. The ultimate aim of 
this work was to gain insight into the role of these proteins 
within the tendon stroma with regard to inflammation and 
ECM turnover and how their expression may relate to per-
sistence of inflammation in tendinopathy.
2 |  MATERIALS AND METHODS
2.1 | Human model of tendinopathy
All procedures and protocols were approved by the Ethics 
Committee under approval numbers Central Network, 
South East Health (HREC/96/55, HREC/14/130) and West 
of Scotland REC (REC14/WS/1035) with informed con-
sent obtained and carried out in accordance with stand-
ard operative procedures. For immunohistochemistry, 
ten supraspinatus tendon samples were collected from 
patients with rotator cuff tears undergoing shoulder sur-
gery. The mean age of the rotator cuff ruptured patients 
was 50 years (range, 30-62 years)—the mean tear size was 
2.2 cm2 (range 1-4 cm2). Samples of the subscapularis ten-
don were also collected from the same patients. Patients 
were only included if there was no clinically detectable 
evidence of subscapularis tendinopathy on a preoperative 
MRI scan as determined by a musculoskeletal radiologist 
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or macroscopic damage to the subscapularis tendon at the 
time of arthroscopy as determined by the senior author 
(NLM)—by these criteria, they represented a preclinical 
cohort. In this cohort, all patients fulfilled the following 
criteria: (a) a history of shoulder pain and dysfunction, (b) 
no previous surgery on the affected shoulder, (c) no radio-
graphic sign of fracture of the shoulder, and (d) no history 
of RA or osteoarthritis.
An independent control group was obtained comprising 
ten samples of subscapularis tendon collected from patients 
undergoing arthroscopic surgery for shoulder stabilization 
without rotator cuff tears, no previous shoulder surgery, no 
radiographic signs of shoulder fracture, or history of RA or 
OA. The absence of rotator cuff tears was confirmed by ar-
throscopic examination. The mean age of the control group 
was 23  years (range, 16-28  years). For mRNA expression, 
fourteen (mean 49 years range, 30-65 years) early tendinop-
athy (subscapularis) samples, 12 late (mean 54 years range, 
38-68 years, mean tear size 2.0 cm2 (range 1-4.5 cm2).) ten-
dinopathy (supraspinatus) samples were utilized while 8 
hamstring tendons (mean 23 years (range, 15-25 years) ob-
tained at the time of routine anterior cruciate ligament re-
construction were employed as an independent control group. 
Additionally, standardized patient demographics were ob-
tained preoperatively and included the duration of shoulder 
symptoms experienced by the patient and the number of sub-
acromial steroid injections.
2.2 | Cell culture and treatments
Normal and tendinopathic human tendon-derived cells were 
explanted form hamstring tendons of patients undergoing 
anterior ligament reconstruction or supraspinatus tendon 
from patients undergoing rotator cuff repair, respectively. 
Patients were age ranged from 18 to 25. Hamstring tendons 
were cut into 2 mm3 pieces and placed in RPMI 1640 sup-
plemented with 10% heat-inactivated fetal bovine serum 
(FBS), 100  µg/mL penicillin, 100  µg/mL streptomycin, 
and 2 nmol/L L-glutamine (all Thermo Fisher Scientific). 
Explants were maintained in a humidified environment at 
37°C, 5% CO2 to allow tenocytes to adhere. Medium was 
replenished every 5 days until cells were confluent. Tissue 
was then removed, and cells were placed in fresh medium. 
Cells were passaged using trypsin-EDTA (Sigma-Aldrich). 
Normal and tendinopathic tenocytes from the second or 
third passage were seeded at 2.5 × 104/mL in 24 well cul-
ture plates and allowed to rest for 48 hours prior to siRNA 
transfection and stimulation.
2.3 | siRNA transfection and tenocyte 
stimulation
In order to knockdown proteins expressed on the tenocyte 
surface, tenocytes were transfected using Silencer Select 
predesigned siRNAs (PDPN, assay ID S20884, VCAM-1 
assay ID S14760, Thermo Fisher Scientific) or a scrambled 
negative control (miRIDIAN microRNA Mimic Negative 
Control #1, Horizon). The following transfection proto-
col using DharmaFECT 3 (Dharmacon) was adapted from 
the manufacturer's recommended protocol. DharmaFECT 
3 and OptiMEM (Thermo Fisher Scientific) were added to 
an eppendorf. 10  μmol/L stock concentration siRNA and 
OptiMEM were added to a separate eppendorf and incu-
bated at room temperature for five minutes. The contents 
of both were subsequently mixed and incubated at room 
temperature for 15 minutes. The medium in which the cells 
were cultured was replenished with 200 μL of fresh medium 
and 50 μL of the transfection mixture was added for a total 
volume of 250 μL (siRNA concentration 25 nmol/L) in a 24 
well plate. The cells were incubated at 37°C in a CO2 incu-
bator for 48 hours. Cells were then retransfected for a fur-
ther 24 hours using the same protocol. Transcript and protein 
knockdown were measured by qPCR and flow cytometry on 
a BD Fortessa, respectively. Antibodies for flow cytometry 
were purchased from Biolegend (Table 1).
Following 72 hours transfection, cells were washed and 
medium was replaced with RPMI containing 10 ng/mL re-
combinant human IL-1β and incubated for 24 hours before 
harvesting of supernatants and cell lysates.
2.4 | RNA extraction, cDNA synthesis, and 
real-time qPCR
Tendon tissue was placed in RNA later solution (Ambion) 
and stored at  −  20°C. Tissue samples were homogenized 
in PureLink lysis buffer containing 1% 2-mercaptoethanol 
using a Qiagen Tissue Lyser LT. Total RNA was isolated 
using the PureLink RNA Mini Kit (Thermo Fisher Scientific) 
according to manufacturer's instructions.
Fluorophore Clone Isotype
Catalogue 
number
Podoplanin PerCP/Cy5.5 NC-08 Rat IgG2a k 337011
VCAM-1 PE STA Mouse IgG1 k 305805
T A B L E  1  Antibodies used for flow 
cytometry
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Cells were placed in PureLink lysis buffer containing 1% 
2-mercaptoethanol, and RNA was extracted using mini col-
umns according to the PureLink protocol. RNA concentra-
tion and purity were determined using a spectrophotometer 
(Nanodrop 2000, Thermo Scientific). 100  ng of RNA was 
converted to cDNA using High Capacity cDNA reverse tran-
scription kit (Thermo Fisher Scientific) according to manu-
facturer's instructions. cDNA was diluted 1 in 5 using RNase 
free water. qPCR was performed using PowerUp Sybr Green 
Mastermix (Thermo Fisher Scientific) and 1 μl cDNA was 
used per reaction with 0.1  μmol/L of forward and reverse 
primers. Each sample was run in duplicate and normalized 
to GAPDH or 18 S endogenous control. Data represent rela-
tive mRNA expression (2−ΔCT) or fold change from untreated 
cells (2−ΔΔCT) (Table 2).
Primers (Integrated DNA Technologies) were as follows:
2.5 | Measurement of cytokine release 
by ELISA
Cell culture supernatants were collected from transfected 
tenocytes and the concentrations of IL-6, IL-8, and CCL2 
were determined using commercially available ELISA kits 
(Thermo Fisher Scientific). Cell culture supernatants were 
diluted with assay diluent to achieve concentrations within 
the specified range. Optical density was measured at 450 nm 
by a microplate reader.
2.6 | Histology and immunohistochemistry
Samples were stained with H&E and toluidine blue for de-
termination of the degree of tendinopathy as assessed by a 
modified version of the Bonar score (Grade 4  =  marked 
tendinopathy, Grade 3  =  advanced tendinopathy, Grade 
2  =  moderate degeneration, Grade 1  =  mild degeneration, 
Grade 0 = normal tendon). This included the presence or ab-
sence of edema and degeneration together with the degree of 
fibroblast cellularity and chondroid metaplasia. Thereafter, 
sections were stained with a range of primary antibodies di-
rected against the following markers: podoplanin (Biolegend, 
Cambridge UK), VCAM-1, CD248 (R and D systems, UK).
Endogenous peroxidase activity was quenched with 3% 
(v/v) H2O2, and non-specific antibody binding blocked with 
2.5% horse serum in Tris buffered saline (TBS) solution with 
detergent Tween20 (TBST) buffer for 30  minutes. Antigen 
retrieval was performed in 0.01 M citrate buffer for 20 min-
utes in a microwave. Sections were incubated with primary 
antibody in 2.5% (w/v) horse serum/human serum/TBST at 
4°C overnight. After two washes, slides were incubated with 
Vector ImmPRESS Reagent kit as per manufacturer's instruc-
tions for 30 minutes. The slides were washed and incubated 
with Vector ImmPACT DAB chromagen solution for 2 min-
utes followed by extensive washing. Finally, the sections were 
counterstained with hematoxylin.
Images were captured using Apple Open laboratory 
software. Positive (human tonsil tissue) control specimens 
were included, in addition to the surgical specimens for 
each individual antibody staining technique. Omission of 
primary antibody and use of negative control (human OA 
samples and human tendon samples) isotypes and a positive 
control (human tonsil samples) confirmed the specificity of 
staining.
We applied a scoring system based on previous methods 
to quantify the immunohistochemical staining. Five random 
high-power fields (×400 magnification) were evaluated by 
two independent assessors (NLM,GACM). In each field, the 
number of positive and negatively stained cells was counted 
and the percentage of positive cells was calculated.
2.7 | Statistical analysis
Comparisons between groups were made with Kruskal-
Wallis One-Way Analysis of Variance on ranks, Ordinary 
One-Way ANOVA with Tukey's correction for multiple 
comparisons, Friedman test with Dunn's correction for mul-
tiple comparisons, using Graph Pad Prism 5 software. In all 
analyses, P < .05 was considered statistically significant.
T A B L E  2  Primer sequences
Target Forward Reverse
18S 5′-GTAACCCGTTGAACCCCATT-3′ 5′-CCATCCAATCGGTAGTAGCG-3′
Col1a1 5′-CAATGCTGCCCTTTCTGCTCC-3′ 5′-CACTTGGGTGTTTGAGCATTG-3′
Col3a1 5′- TATCGAACACGCAAGGCTGTG-3′ 5′-CACTTGGGTGTTTGAGCATTG-3′
Tenascin C 5′-CTTTGGCTGGGTTGCTTGAC-3′ 5′-GTGCCAGGAGACCGTACCAC-3′
Decorin 5′-CGCCTCATCTGAGGGAGCTT-3′ 5′-TACTGGACCGGGTTGCTGAA-3′
PDPN 5′-CTTGACAACTCTGGTGGA-3′ 5′-GGGCTTGGACTTGTTCTTG-3′
VCAM1 5′-GCAAGTCTACATATCACCCAAGA-3′ 5′-TAGACCCTGGCTGGAACA-3′
CD248 5′-CTGTGCTCGGCAAGACC-3′ 5′-CCCAAATCCCAAGGGAAGAT-3′
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3 |  RESULTS
3.1 | Podoplanin and VCAM-1 expression is 
increased in tendinopathic tissue
RT-PCR of whole tendon tissue showed a significant in-
crease in podoplanin and VCAM-1 expression between con-
trol and late tendinopathy (Figure 1A,B P < .01). A modest 
increase in expression of both markers was observed in early 
tendinopathy; however, this was not significant vs control 
or late tendinopathic samples. No apparent changes in ex-
pression of CD248 transcript were observed (Figure  1C). 
Immunohistochemical staining of tendinopathic sections 
showed positive staining of PDPN, VCAM-1, and CD248 
in both control and tendinopathic sections (Figure  1D-H). 
Quantitative analysis revealed significant increases in podo-
planin (P < .05 control vs late tendinopathy) and VCAM-1 
(P  <  .05 control vs late tendinopathy) expression between 
control and tendinopathic sections (Figure 1E-I). Conversely, 
CD248 expression remained constant between control and 
both disease groups.
We next examined the effect of an inflammatory stimulus 
on expression of PDPN, VCAM-1, and CD248 which showed 
that the inflammatory molecules IL-1β and TNF-α increased 
expression of PDPN, approximately 2.5 fold in both in-
stances (Figure S1A). TNF-α induced a significant increase 
in VCAM-1 expression (Figure S1B, P < .05). IL-1β stimu-
lation also resulted in a marked increase in VCAM-1 expres-
sion. Interestingly, upon stimulation, expression of CD248 in 
tenocytes appeared to decrease slightly (Figure S1C).
3.2 | Podoplanin and VCAM-1 knockdown 
have no direct effect on the inflammatory 
secretome of tenocytes
In order to assess the effect of the presence and relative deple-
tion of podoplanin and VCAM-1 expression on the intrinsic 
behavior of tenocytes, we developed an siRNA knockdown 
procedure using commercially available siRNA. On aver-
age, we obtained 80% knockdown in podoplanin protein 
expression and 92% reduction in PDPN transcript by RT-
PCR (Figure S2). Similarly, we observed an average reduc-
tion of 71% VCAM-1 protein and 90% VCAM-1 transcript 
in siRNA-transfected tenocytes relative to scramble control 
(Figure S2).
To test the effect of stromal surface marker knockdown 
on the inflammatory secretome, normal and tendinopathic 
tenocytes were subject to podoplanin and VCAM-1 knock-
down and subsequently stimulated with 10 ng/mL IL-1β to 
invoke an inflammatory response. Addition of IL-1β to the 
culture system induced significant increases in release of 
IL-6, IL-8, and CCL2 from tenocytes compared with controls 
(untransfected control, scramble control and podoplanin/
VCAM-1 siRNA vs IL-1β stimulation) (Figure 2, P <  .05, 
0.01 or 0.001) (Figure 3). We found no significant effect of 
podoplanin or VCAM1 knockdown alone on release of IL-6, 
IL-8 (Figure  4C,D, Figure  5C,D), or CCL2 (Figure  4E,F, 
Figure 5E,F) in normal or tendinopathic tenocytes compared 
with untransfected tenocytes and scramble transfection con-
trol. Similarly, knockdown of podoplanin or VCAM-1 did 
not affect the magnitude of cytokine/chemokine release in 
response to IL-1β stimulation.
3.3 | Podoplanin or VCAM-1 knockdown 
does not alter expression of matrix proteins 
in tenocytes
The effect of podoplanin and VCAM-1 knockdown and si-
multaneous stimulation with IL-1β on matrix production 
was measured by RT-qPCR using a panel of genes associ-
ated with matrix regulation by tenocytes. Neither podo-
planin knockdown nor IL-1β stimulation appeared to have 
any effect on production of collagen 1 (COL1A1) in nor-
mal and tendinopathic tenocytes (Figure 6A,B). There was 
a trend toward increased expression of matrix proteins as-
sociated with tendinopathy including collagen 3 (COL3A1) 
(Figure 6C,D), tenascin C (TNC) (Figure 6E,F), and decorin 
(DCN) (Figure  6G,H) in response to IL-1β stimulation in 
normal and tendinopathic tenocytes; however, podoplanin 
knockdown did not appear to have any demonstrable effect.
Similarly, VCAM-1 knockdown did not appear to have 
any effect on expression on matrix proteins in normal or ten-
dinopathic tenocytes compared with control (Figure  7A-J). 
As observed previously, there was a trend of increased ex-
pression of COL3A1 (Figure 7C,D) and TNC (Figure 7G,H) 
in normal and tendinopathic tenocytes in response to IL-1β 
stimulation.
4 |  DISCUSSION
In the context of the tendinopathy, little is known about the 
properties of stromal cells and whether phenotypic character-
istics may direct pathology. This study sought to address the 
physiological significance of stromal “activation” markers 
in tendinopathy using an in vitro loss-of-function approach. 
Data from our human tendinopathy model showed significant 
variations in podoplanin and VCAM-1 expression between 
healthy and diseased states which is in agreement with previ-
ous findings.19 We did not, however, observe any changes in 
CD248 between control and tendinopathy groups as antici-
pated in any of our ex vivo or in vitro studies. Consequently, 
we proceeded to knock down expression of podoplanin and 
VCAM-1 in normal and tendinopathic tenocytes.
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F I G U R E  1  PDPN, VCAM-1, and CD248 expression in tendinopathy. Relative mRNA expression (2^-ΔCT) of (A) PDPN (B) VCAM-1 
(C) CD248 expression in control (hamstring tendon, n = 9), early tendinopathy (intact subscapularis biopsy, n = 10) and late tendinopathy (torn 
supraspinatus tendon, n = 14). Data represent mean ± SEM relative to housekeeping gene GAPDH (mean of duplicate analysis). * P < .05, 
**P < .01, (Kruskal-Wallis test) vs control. Control and late tendinopathy sections stained with antibodies directed against PDPN (D) VCAM-1 (F) 
CD248 (H). Quantitative expression of (E) PDPN (G) VCAM-1 (I) CD248 depicts mean percentage of positive cells per sample based on 5 high-
power fields, Data represent mean ± SEM, n = 5 for control tendon, early and late tendinopathy. * P < .05 (Friedman test with Dunn's multiple 
comparisons)
F I G U R E  2  PDPN, VCAM-1, and CD248 expression in tenocytes stimulated with IL-1β and TNF-ɑ. Fold change in mRNA expression (2- Δ 
Δ CT) of (A) PDPN (B) VCAM-1 (C) CD248 expression in normal tenocytes. Data represent mean ± SEM relative to housekeeping gene GAPDH 
(mean of duplicate analysis). * P < .05 (Friedman test with Dunn's multiple comparisons)
F I G U R E  3  Podoplanin and VCAM-1 
knockdown in tenocytes. siRNA knockdown 
of podoplanin in scramble control and 
transfected tenocytes (siPDPN/siVCAM-1) 
(A & B) expressed as % positive singlet 
cells based on isotype control gating, 
n = 3 (C & D) percentage knockdown of 
podoplanin measured by RT-PCR (relative 
to 18S endogenous control), n = 3 (E & 
F) representative histogram of podoplanin 
surface expression in transfected tenocytes 
relative to scramble control. All data 
represent mean ± SEM, n = 3
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Loss of podoplanin and VCAM-1 expression did not 
appear to have any bearing on the cytokine/chemokine pro-
file of tenocytes (measured by expression of IL-6, IL-8, 
and CCL2) at rest nor did it direct any apparent changes 
in matrix regulation. From our results, it is evident that 
IL-1β induces expression of podoplanin and VCAM-1 in 
tenocytes that is accompanied by significant production of 
inflammatory mediators and matrix proteins reflecting the 
molecular changes observed in tendinopathy. Interestingly, 
knockdown of podoplanin and VCAM-1 did not affect the 
responsiveness of tenocytes to an inflammatory challenge 
indicating there is no direct relationship between expres-
sion of stromal “activation” markers and regulation of in-
flammation and matrix turnover. For this relationship to 
be deemed directly functional, we would have expected to 
see a correlation between cytokine/chemokine production 
and loss of podoplanin/VCAM-1 expression. However, 
tenocytes lacking podoplanin/VCAM-1 expression ap-
peared to remain equally as responsive as control cells 
upon stimulation indicating they have retained their in-
flammatory properties.
Studies in the context of wound healing and fibroprolif-
erative disease have outlined a clear relationship between 
function and phenotype whereby fibroblast “activation” 
(characterized by expression of α-SMA) is accompanied 
by excessive pathological matrix production.27,28 By con-
trast, our loss-of-function studies did not identify any such 
tangible relationship between expression of surface proteins 
and inflammation/matrix regulation by tenocytes. The first 
observation of “activation” of fibroblasts and their partici-
pation in the innate immune response was described in the 
rheumatoid synovium whereby engagement of TLR ligands 
on the cell surface resulted in the release of chemokines.29 
As such, we propose that the “activation” state of tenocytes 
F I G U R E  4  Cytokine release from 
tenocytes with podoplanin knockdown.
IL-6, IL-8, and CCL2 release from (A, C, 
E) normal tenocytes (B, D, F) tendinopathic 
tenocytes left untransfected (control), 
transfected with scramble control and 
transfected with podoplanin siRNA in the 
presence or absence of 10 ng/mL IL-1β 
stimulation. P < .05, **P < .01 (One-way 
ANOVA with Tukey's multiple comparisons 
test). All data represent mean ± SEM, 
n = 3
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is more appropriately measured by functional properties in-
cluding relative expression of inflammatory mediators and 
matrix proteins rather than potentially arbitrary phenotypic 
properties.
As podoplanin and VCAM-1 are predominantly expressed 
on the cell surface we acknowledge, there are limitations to 
closed system in vitro models that exclude potential recep-
tor-ligand interactions. CLEC-2 is the only known ligand 
for podoplanin and is expressed at low levels on DCs and 
macrophages.30 It is plausible that engagement of the podo-
planin/CLEC-2 axis at the tenocyte-immune cell interface 
is required to activate signaling cascades that regulate the 
immune response.21 Similarly, VCAM-1 is associated with 
leukocyte trafficking during inflammation through inter-
action with α4β1 integrin.31 As such, it is possible that in-
creased and persistent expression podoplanin and VCAM-1 
on the tenocyte surface in disease is a priming mechanism 
that allows stromal cells to engage with infiltrating cells more 
readily. This may be a result of epigenetic imprinting based 
on previous trauma or immediate microenvironmental cues 
present in the tendon stroma.11
Recent transcriptomic studies have described the pres-
ence of several “subpopulations” of fibroblasts in RA. 
Anatomical localization of fibroblast subpopulations has 
been identified through the sublining and lining later of 
the synovium based on surface marker expression.32-34 
Gene expression analysis and in vitro validation have also 
revealed distinct inflammatory profiles of subsets defined 
by differential cytokine/chemokine expression, enhanced 
leukocyte recruitment and activation of signaling path-
ways.32,35 We postulate that subpopulations of tenocytes 
with varying surface marker profiles, not limited to those 
described herein, exist within the tendon stroma. Such pop-
ulations may possess varying immunological properties 
including cytokine/chemokine repertoire and regulation 
of ECM turnover. The concepts of fibroblast “activation” 
and heterogeneity are inextricably linked and it is possible 
they represent a “cause and effect” phenomenon whereby 
F I G U R E  5  Cytokine release from 
tenocytes with VCAM-1 knockdown. IL-6, 
IL-8, and CCL2 release from (A, C, E) 
normal tenocytes (B, D, F) tendinopathic 
tenocytes left untransfected (control), 
transfected with scramble control and 
transfected with podoplanin siRNA in the 
presence or absence of 10 ng/mL IL-1β 
stimulation. P < .05, **P < .01 (One-way 
ANOVA with Tukey's multiple comparisons 
test). All data represent mean ± SEM, 
n = 3
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fibroblasts exposed to inflammatory stimuli in the early 
stages of disease give rise to distinct subpopulations pres-
ent in established pathology.
While the translation of concepts between disease 
states that display similar characteristics is invaluable to 
advancement of knowledge, caution should be exercised 
with regards to universal terminology such as stromal 
“activation.” When considering stromal biology, drawing 
comparisons between markers expressed on tenocytes in 
tendinopathic tendon and RA synovium (RA-FLS) or the 
F I G U R E  6  Podoplanin knockdown 
does not directly alter matrix regulation 
by tenocytes. (A) COL1A1(B) COL3A1 
(C) TNC (D) DCN expression in normal or 
tendinopathic tenocytes transfected with 
scramble control or VCAM-1 siRNA in 
the presence or absence of 10 ng/mL IL-1β 
stimulation. All data are normalized to 
18S housekeeping gene and expressed as 
fold change relative to scramble control, 
data represent mean ± SEM, n = 3
F I G U R E  7  VCAM-1 knockdown 
does not directly alter matrix regulation 
by tenocytes. (A) COL1A1 (B) COL3A1 
(C) TNC (D) DCN expression in normal or 
tendinopathic tenocytes transfected with 
scramble control or VCAM-1 siRNA in 
the presence or absence of 10 ng/mL IL-1β 
stimulation. All data are normalized to 
18S housekeeping gene and expressed as 
fold change relative to scramble control, 
data represent mean ± SEM, n = 3
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tumor microenvironment (cancer-associated fibroblasts) 
may be problematic as each disease state displays a unique 
immune landscape.17,35 For example, in chronic tendon 
disorders the magnitude of immune cell infiltration to 
the damaged tissue is far less marked than that of an per-
sistently inflamed joint and different immune cell popula-
tions predominate through stages of disease progression.3 
It is evident that chronic exposure to inflammatory condi-
tions has a lasting effect on the properties stromal cells; 
however, such properties are likely to be highly tissue spe-
cific and dependent upon local microenvironmental cues.
5 |  CONCLUSIONS
The aim of this study was to assess the effect of dampening 
“activation” of tendon stromal cells through knockdown of 
surface proteins podoplanin and VCAM-1. We conclude 
that tenocytes lacking expression of “activation” markers 
podoplanin and VCAM-1 do not display any discernible 
changes in typical disease-associated behaviors and remain 
pathogenic. “Activated” stromal cells are said to be primed 
to respond to inflammation through stromal memory; how-
ever, we found neither the relative presence nor absence 
of podoplanin/VCAM-1 had any effect on the tenocyte's 
response to a subsequent inflammatory challenge. Taken 
together, it is evident that expression of these surface pro-
teins does not directly affect the intrinsic workings of the 
cell with regard to synthesis and release of inflammatory 
mediators and matrix proteins that is typical under condi-
tions of tissue stress. We propose that, in the context of 
tendinopathy, the term “activation” is more appropriately 
associated with alterations in tenocyte behavior that induce 
changes in the stromal microenvironment and overall tis-
sue architecture. Identifying mechanisms through which 
stromal cells contribute to perpetuation of active disease 
may aid in attenuating pathological inflammation in tendi-
nopathy through pharmacologic intervention.
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